Your search returned 37 results.

Results
	1.	Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen. [electronic resource] by Shaefer, Mark S Producer: 20041006 In: The Annals of pharmacotherapy vol. 38 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States. [electronic resource] by Ross, Lisa L Shortino, Denise Shaefer, Mark S Producer: 20190716 In: AIDS research and human retroviruses vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects. [electronic resource] by Small, Catherine Butkus Margolis, David A Shaefer, Mark S Ross, Lisa L Producer: 20170628 In: BMC infectious diseases vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. [electronic resource] by Paulsen, Denise Liao, Qiming Fusco, Gregory St Clair, Marty Shaefer, Mark Ross, Lisa Producer: 20021213 In: AIDS research and human retroviruses vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. [electronic resource] by Watson, Maria E Patel, Lisa G Ha, Belinda Wannamaker, Paul Cuffe, Robert Shaefer, Mark Producer: 20100204 In: AIDS patient care and STDs vol. 23 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. [electronic resource] by Ross, Lisa Lim, Michael L Liao, Qiming Wine, Brian Rodriguez, Allan E Weinberg, Winkler Shaefer, Mark Producer: 20070525 In: HIV clinical trials vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen. [electronic resource] by Rodriguez, Allan Hill-Zabala, Christina Sloan, Louis Jefferson, Thomas Yau, Linda Watson, Maria Irlbeck, David Shaefer, Mark Producer: 20060302 In: Journal of acquired immune deficiency syndromes (1999) vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). [electronic resource] by Sosa, Nestor Hill-Zabala, Christina Dejesus, Edwin Herrera, Gisella Florance, Allison Watson, Maria Vavro, Cindy Shaefer, Mark Producer: 20060110 In: Journal of acquired immune deficiency syndromes (1999) vol. 40 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir. [electronic resource] by Robertson, Kevin Maruff, Paul Ross, Lisa L Wohl, David Small, Catherine B Edelstein, Howard Shaefer, Mark S Producer: 20200907 In: Journal of neurovirology vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). [electronic resource] by Kumar, Princy N Salvato, Patricia LaMarca, Anthony DeJesus, Edwin Patel, Parul McClernon, Daniel Florance, Allison Shaefer, Mark S Producer: 20090429 In: AIDS research and therapy vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. [electronic resource] by Markowitz, Martin Hill-Zabala, Christina Lang, Joseph DeJesus, Edwin Liao, Qiming Lanier, E Randall Davis, E Anne Shaefer, Mark Producer: 20050913 In: Journal of acquired immune deficiency syndromes (1999) vol. 39 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study. [electronic resource] by Adkison, Kimberly Wolstenholme, Allen Lou, Yu Zhang, Zhiping Eld, Amy Perger, Teodora Vangerow, Harald Hayward, Katy Shaefer, Mark McCoig, Cynthia Producer: 20190412 In: Clinical pharmacology and therapeutics vol. 103 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	13.	Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. [electronic resource] by Bartlett, John A Johnson, Judy Herrera, Gisela Sosa, Nestor Rodriguez, Alan Liao, Qiming Griffith, Sandy Irlbeck, David Shaefer, Mark S Producer: 20061212 In: Journal of acquired immune deficiency syndromes (1999) vol. 43 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	14.	Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. [electronic resource] by Cohen, Calvin Dejesus, Edwin Lamarca, Anthony Young, Benjamin Yau, Linda Patel, Lisa Vavro, Cindy Wire, Mary Beth Wannamaker, Paul Shaefer, Mark Producer: 20110106 In: HIV clinical trials vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	15.	Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. [electronic resource] by Young, Benjamin Squires, Kathleen E Tashima, Karen Henry, Keith Schneider, Stefan LaMarca, Anthony Zhao, Henry H Ross, Lisa L Shaefer, Mark S Producer: 20180305 In: HIV clinical trials vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	16.	Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. [electronic resource] by Nan, Cassandra Shaefer, Mark Urbaityte, Rimgaile Oyee, James Hopking, Judy Ragone, Leigh Perger, Teodora Win, Beta Vangerow, Harald McCoig, Cynthia Vannappagari, Vani Publication details: Open forum infectious diseases May 2018 In: Open forum infectious diseases vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	17.	Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus. [electronic resource] by Ruane, Peter J Richmond, Gary J DeJesus, Edwin Hill-Zabala, Christina E Danehower, Susan C Liao, Qiming Johnson, Judy Shaefer, Mark S Producer: 20040819 In: Pharmacotherapy vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	18.	First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. [electronic resource] by Young, Benjamin Squires, Kathleen Patel, Parul Dejesus, Edwin Bellos, Nicholaos Berger, Daniel Sutherland-Phillips, Denise H Liao, Qiming Shaefer, Mark Wannamaker, Paul Producer: 20080924 In: AIDS (London, England) vol. 22 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	19.	ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. [electronic resource] by Squires, Kathleen E Young, Benjamin DeJesus, Edwin Bellos, Nicholaos Murphy, Daniel Ward, Douglas Zhao, Henry H Ross, Lisa L Shaefer, Mark S Producer: 20121211 In: HIV clinical trials vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	20.	HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA [electronic resource] by Mounzer, Karam Hsu, Ricky Fusco, Jennifer S Brunet, Laurence Henegar, Cassidy E Vannappagari, Vani Stainsby, Chris M Shaefer, Mark S Ragone, Leigh Fusco, Gregory P Producer: 20200228 In: AIDS research and therapy vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search

Availability

Authors

Topics

Languages

Your search returned 37 results.